As the ASCO annual meeting approaches, the number of LBA for domestically innovative drugs has reached a new high, with three key investment themes worth noting.

A total of 63 studies were selected as Late-Breaking Abstracts (LBA) at this year's ASCO, including 13 studies from 12 companies based in China; notable domestically developed innovative drugs selected for LBA include AK112 from Akeso Biopharma and sintilimab plus chemotherapy from Innovent Bio; Huatai Securities stated that China's innovative drug sector is rapidly emerging as a defining force in global oncology treatment paradigms, with first-line lung cancer being one of the key focuses at this year’s ASCO.

cls.cnMay 4 14:15

SIRNAOMICS-B: ANNUAL REPORT 2025

HKEXApr 24 17:00 · Announcements

Sirnaomics-B (02257.HK): Proposal to Terminate Existing Share Option Plan and Adopt New Share Option Plan

Gelonghui, April 22nd: Sirnaomics-B (02257.HK) announced that on April 22, 2026, the board of directors proposed the adoption of a share option plan ("2026 Share Option Plan") and the termination of the existing share option plan ("Existing Share Option Plan") adopted by the company on June 28, 2022, subject to shareholder approval. The Existing Share Option Plan was adopted through a shareholder resolution passed on June 28, 2022, and is valid and effective for ten years from the date of adoption. According to the terms of the Existing Share Option Plan, the company may at any time decide to terminate it before its expiration.

Gelonghui FinanceApr 22 17:26

Sirnaomics Unveils New Corporate Logo Without Affecting Shareholder Rights

TipRanksApr 10 20:07

Trump takes action on pharmaceuticals! Import drugs face a maximum tax rate of 100%.

Trump fulfilled his threat by imposing a tariff of up to 100% on certain imported patented drugs. However, giants such as Merck and Eli Lilly and Co had already privately 'negotiated for exemptions.' Who will ultimately bear the brunt?

Golden10 DataApr 3 07:59

Sirnaomics-B (02257) received a shareholding increase of 38,000 shares by its executive director, Pan Honghui.

Sirnaomics-B (02257) announced that the board of directors was informed by the company’s executive director and chairman, Dr. Patrick Lu, that on March 30, 2026, Dr. Lu purchased a total of 38,000 ordinary shares of the company on the open market at an average price of approximately HKD 5.93 per share using personal funds. Following the purchase, Dr. Lu holds an interest in a total of 17,665,700 shares, representing 16.10% of the company’s total issued share capital as of the date of this announcement.

Zhitong FinanceMar 30 23:15